Advancing Precision Oncology with a Matched Tumor-Normal Approach: Insights from the Clinic

Speakers: ​
A. Rose Brannon, PhD​

Director of Clinical Bioinformatics, Memorial Sloan Kettering Cancer Center​

Anita S. Bowman​

Associate Director of Clinical Bioinformatics, Memorial Sloan Kettering Cancer Center​

This webinar presents an in-depth look at how Memorial Sloan Kettering Cancer Center (MSK) is routinely using its molecular assays — MSK-IMPACT and MSK-ACCESS — together to inform precision oncology approaches.​

​MSK-IMPACT is a targeted tissue-based sequencing test for comprehensive genomic profiling. MSK-ACCESS is a liquid biopsy test that enables non-invasive profiling and longitudinal disease monitoring. Together, they provide robust insights that help guide treatment decisions for improved outcomes in patients with advanced cancer. Unlike most tests, MSK leverages matched tumor-normal sequencing to remove germline and clonal hematopoietic variants, revealing genomic alterations of true somatic origin.​

In this webinar, A. Rose Brannon, director of clinical bioinformatics at MSK, and Anita S. Bowman, associate director of clinical bioinformatics at MSK, will:​

  • Highlight the benefits of matched tumor-normal sequencing to reduce biological false positives.​

  • Discuss the clinical utility of combining tissue- and cell-free DNA-based sequencing approaches, with insights from real clinical cases.​

  • Explore opportunities for clinical, translational, and basic research.​

Want to learn more?

One of our experts will be in touch with you shortly!